BioSpace News Archive

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, in collaboration with researchers, announced today that new advances from its positive preclinical study for a multivalent exosome-based mRNA vaccine for COVID-19

FRR will provide a practical overview of the innovative COVID-19 Pandemic Management Platform, Fionet.

In addition to the acquisition of the data, Prof. Nutt has been appointed as Head of Research to lead Awakn’s next generation psychedelic molecule development programme.

Celularity Inc. (“Celularity”), a clinical-stage biotechnology company focused on the development of innovative allogeneic placenta-derived cellular therapies, announced that Robert J. Hariri, M.D., Ph.D., founder, Chairperson and Chief Executive Officer of Celularity, will present a corporate overview as well as participate in a fireside chat and panel discussion during the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021.

Annmarie Chavarria is a visionary leader who will drive development and organizational leadership for Tampa General’s nursing team.

AliveCor, the global leader in FDA-cleared personal electrocardiogram technology and services, announced the appointment of Clyde Hosein as its Chief Financial Officer.

Luminex Corporation (NASDAQ: LMNX) today announced that Homi Shamir, Chairman, CEO & President, and Harriss Currie, Senior Vice President and CFO, plan to participate at the 2021 Barclays Global Healthcare Conference on March 10, 2021 at 8:35 a.m. Eastern Time

Agilent Technologies Inc., announced that Dr. Katharine Knobil is joining Agilent as the company’s chief medical officer.

Primarily associated with minimally invasive procedures that involve tiny incisions, robotic surgeries are being rapidly adopted by hospitals for treating an array of health conditions.

Increase in geriatric population along with major prevalence of mixed incontinence in women could augment new growth strides in the disposable incontinence products market.